Key result
Intravenous GD-MSC therapy lowers serum TGF-β1 and NT-proBNP at 6 months in canine myxomatous mitral disease.
Why the study?
Myxomatous mitral valve disease (MMVD) is primarily degenerative and lacks recommended routine pharmacological treatment at stage B1, prompting this exploratory evaluation of mesenchymal stem cells (MSCs), which can promote tissue repair and exert immunomodulatory and anti-inflammatory effects.
Does intravenous administration of allogeneic canine gonadal tissue-derived mesenchymal stem cells reduce serum TGF-β1, NT-proBNP, and echocardiographic progression in dogs with stage B1 myxomatous mitral valve disease?
Does intravenous administration of allogeneic canine gonadal tissue-derived mesenchymal stem cells reduce serum TGF-β1, NT-proBNP, and echocardiographic progression in dogs with stage B1 myxomatous mitral valve disease?
In this small prospective veterinary pilot study, intravenous allogeneic gonadal-derived MSC therapy was associated with favorable 6-month reductions in circulating biomarkers (TGF-β1, NT-proBNP) and cardiac remodeling indices in dogs with early stage B1 myxomatous mitral valve disease.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in stage B1 MMVD; leaves open whether MSCs modify early progression pending randomized trials.
Mesenchymal stem cells (MSCs) are multipotent stromal cells that can promote tissue repair and exert immunomodulatory and anti-inflammatory effects. Myxomatous mitral valve disease (MMVD) is primarily degenerative, and routine pharmacological treatment is not recommended at stage B1. This exploratory study assessed changes in serum transforming growth factor-β1 (TGF-β1) following systemic administration of allogeneic canine gonadal tissue-derived MSCs (GD-MSCs) in client-owned dogs with stage B1 MMVD, with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and echocardiographic measurements as secondary outcomes. The analyzed cohort comprised ten dogs, allocated according to owners’ treatment choices (MSC, n = 5; control, n = 5). Treated dogs received intravenous allogeneic GD-MSCs (1 × 10 6 cells/kg) at monthly intervals for four administrations and were followed for 6 months. Compared with controls, MSC-treated dogs showed greater decreases from baseline to six months in serum TGF-β1 ( p = 0.0317), NT-proBNP ( p = 0.0079), and body weight-normalized anterior mitral leaflet area ( p = 0.0079; Holm- and Bonferroni-adjusted p = 0.0238). The NT-proBNP mean-change difference was − 530.38 pmol/L (Welch 95% confidence interval − 846.19 to − 214.57), although absolute concentrations did not differ significantly between groups at either visit. Changes in body weight-normalized left ventricular end-diastolic internal diameter (LVIDDN) ( p = 0.0397) and vertebral left atrial size (VLAS) ( p = 0.0079) also decreased to a greater extent in the MSC group. GD-MSC administration was associated with six-month changes in circulating biomarkers and selected cardiac imaging measurements in dogs with stage B1 MMVD. These prospective comparative observations support further evaluation of MSCs in early MMVD, with larger randomized studies needed to determine whether the initial signals translate into sustained clinical benefit.
No takes yet. Share an insight, caveat, or question.
Jeung et al. (2026) studied Stage B1 myxomatous mitral valve disease (MMVD) in dogs (n=10). Allogeneic canine gonadal tissue-derived mesenchymal stem cells (GD-MSCs) vs. Control (n = 5, allocated by owner choice) was evaluated on Changes in serum transforming growth factor-β1 (TGF-β1) from baseline to 6 months (p=0.0317).
Synapse has enriched 10 related papers. Consider them for comparative context: